DEXCOM INC — Director's Dealing 2022

Mar 11, 2022

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: DEXCOM INC (DXCM)
CIK: 0001093557
Period of Report: 2022-03-08

Reporting Person: Sylvain Jereme M (EVP, Chief Financial Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2022-03-08	Common Stock	A	5297	$0.001	Acquired	19959	Direct
2022-03-09	Common Stock	D	491	$406.0567	Disposed	19468	Direct
2022-03-09	Common Stock	D	844	$406.0567	Disposed	18624	Direct
2022-03-09	Common Stock	D	424	$406.0567	Disposed	18200	Direct
2022-03-09	Common Stock	D	192	$406.0567	Disposed	18008	Direct

Footnotes

F1: Represents a grant of restricted stock units that are exempt from Section 16 b-3 and are subject to vesting in three equal annual installments from the date of grant. Share units represent a contingent right to receive one share of DexCom, Inc. Common Stock.

F2: Included in this number are 13,583 unvested restricted stock units, 5,297 of which were granted on March 8, 2022 and shall vest through March 8, 2025, 2,925 of which were granted on December 15, 2021 and shall vest through December 15, 2024, 3,534 of which were granted on March 8, 2021 and shall vest through March 8, 2024, 1,827 of which were granted on March 8, 2020 and shall vest through March 8, 2023.

F3: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of RSUs. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.